Abeona Therapeutics Announces Q4 2025 Financial Results, Upcoming Conference

The biopharmaceutical company will host a conference call and participate in the 2026 Leerink Global Healthcare Conference.

Published on Mar. 3, 2026

Got story updates? Submit your updates here. ›

Abeona Therapeutics Inc. (Nasdaq: ABEO) announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress. The company will also participate in a fireside chat at the 2026 Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 8:40 a.m. Eastern Time.

Why it matters

As a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, Abeona's financial performance and participation in industry conferences are closely watched by investors and the healthcare community.

The details

Abeona will host the conference call to discuss its Q4 and full year 2025 financial results and corporate progress. The company will also participate in a fireside chat at the 2026 Leerink Global Healthcare Conference, where it will provide updates on its pipeline and commercial activities.

  • Abeona will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET.
  • Abeona will participate in a fireside chat at the 2026 Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 8:40 a.m. Eastern Time.

The players

Abeona Therapeutics Inc.

A commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona's ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).

Got photos? Submit your photos here. ›

The takeaway

Abeona's upcoming financial results and industry conference participation demonstrate the company's continued progress in developing and commercializing its cell and gene therapy pipeline for serious diseases.